|
gptkbp:instanceOf
|
gptkb:drug
glucagon-like peptide-1 receptor agonist
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
2005
|
|
gptkbp:ATCCode
|
gptkb:A10BJ01
|
|
gptkbp:brand
|
gptkb:Bydureon
gptkb:Byetta
|
|
gptkbp:CASNumber
|
141732-76-5
|
|
gptkbp:compatibleWith
|
gptkb:type_1_diabetes_mellitus
gptkb:diabetic_ketoacidosis
|
|
gptkbp:contraindication
|
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
history of medullary thyroid carcinoma
|
|
gptkbp:derivedFrom
|
gptkb:exendin-4
|
|
gptkbp:discoveredBy
|
gptkb:Amylin_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
2.4 hours (Byetta)
5 days (Bydureon)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
pre-filled pen
extended-release
immediate-release
single-dose vial
|
|
gptkbp:hasMolecularFormula
|
C184H282N50O60S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
exenatide
|
|
gptkbp:KEGGID
|
D04167
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
slows gastric emptying
increases insulin secretion
suppresses glucagon secretion
|
|
gptkbp:metabolism
|
proteolytic degradation
|
|
gptkbp:origin
|
gptkb:Gila_monster_saliva
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinSequence
|
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
16134978
DB01225
|
|
gptkbp:riskFactor
|
thyroid C-cell tumors (in rodents)
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
nausea
vomiting
diarrhea
pancreatitis
|
|
gptkbp:storage
|
refrigeration required
|
|
gptkbp:UNII
|
QZD84WI0J5
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:GLP-1_receptor_agonists
|
|
gptkbp:bfsLayer
|
6
|